Speakers

Expand/Collapse

Saso Cermerski
VP & Head of Discovery & Translation Immunology
Cue Biopharma

Day One

Wednesday February 26, 2020

4:40 pm | Directly Targeting Autoantigen-Specific T-Cells

Ciaran P. Kelly
Professor of Medicine/Chief/Director/Medical Director
Harvard Medical School/Herman L. Blumgart Internal Medicine Firm/Gastroenterology Fellowship Training/Celiac Center

Day One

Wednesday February 26, 2020

10:00 am | Success Story: Gliadin-Encapsulating Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease – Results of A Phase 1/ 2 Placebo-Controlled Clinical Trial

Richard Boismenu
Chief Scientific Officer
IgGenix

Day Two

Thursday February 27, 2020

4:00 pm | Panel: Developing Precision Immune Tolerance Therapeutics

Kei Kishimoto
Chief Scientific Officer
Selecta Biosciences

Day One

Wednesday February 26, 2020

11:40 am | Challenges and Opportunities for Immune Tolerance Induction in AAV Gene Therapy

Antoon Van Oosterhout
Chief Scientific Officer VP R&D
Imcyse

Day One

Wednesday February 26, 2020

2:40 pm | Induction of cytolytic phenotype in human and mouse CD4+ T-cells by MOG-derived Imotopes™ and validation of the immunosuppressive capacity in mouse models of Multiple Sclerosis

Simi Ahmed
Director of Research & Lead of the Immune Therapies Program
JDRF

Day One

Wednesday February 26, 2020

9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics

Shinu John
Associate Director, Immune Tolerance
SQZ Biotechnologies

Day One

Wednesday February 26, 2020

4:10 pm | Cell Squeezing RBCs to Create Therapy for Inducing Antigen- Specific Tolerance

Jean Van Rampelbergh
VP Clinical & Regulatory
Imcyse

Day Two

Thursday February 27, 2020

11:00 am | Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes

Randolph Noelle
Professor, Dartmouth Medical School; Co- Founder & Vice Chair
ImmuNext

Day Two

Thursday February 27, 2020

3:30 pm | Magnifying Antigen-Specific Tolerance

Jose Carballido
Executive Director (Translational Medicine/ Preclinical Safety)
Novartis

Day One

Wednesday February 26, 2020

9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics

Charlotte Fribert
Chief Executive Officer
Toleranzia AB

Day Two

Thursday February 27, 2020

1:30 pm | TOL2 and TOL3: Antigen Specific Tolerogenic Therapies for the Treatment of Myasthenia Gravis and ANCA vasculitis

David Wraith
Founder & Chief Scientific Officer – Apitope; Director, Institute of Immunology & Immunotherapy
University of Birmingham

Day One

Wednesday February 26, 2020

1:40 pm | Developing Robust Data to Valid MoA & Demonstrate Clinical Proof of Concept

9:10 am | Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics

Gerald Rea
Chief Executive Officer
Toralgen

Day Two

Thursday February 27, 2020

2:30 pm | Treg-Enhancing Approaches to Drive Tolerance Induction in the Clinic

Brendan Classon
Vice President Research & Development
Parvus Therapeutics

Day One

Wednesday February 26, 2020

3:10 pm | Developing Biomarker Assays that Can Inform Both Target Engagement & Pharmacodynamic Effects

AbdulSalam Shaaban
Senior Director
Rubius Therapeutics

Li Zhang
Assistant Professor Medicine-Endocrinology
Baylor College of Medicine

Day Two

Thursday February 27, 2020

9:40 am | Monoclonal Antibodies Specific for Multiple Novel Targets to Suppress Type 1 Diabetes (t1d).

Marius Albulescu
Global Clinical Program Lead
AstraZeneca

Day One

Wednesday February 26, 2020

3:40 pm | Biomarker-Driven Trial Design and Patient Stratification for Clinical Trials

Dr Bruce Mazer
Executive, Chief Scientific Officer
Executive, Chief Scientific Officer

Day One

Wednesday February 26, 2020

2:10 pm | Developing Suitable Preclinical Models to Enable Successful Clinical Translation

Karsten Sauer
Vice President of Immunology
Repertoire Immune Medicines

Day Two

Thursday February 27, 2020

9:10 am | Success Story: Overcoming Challenges in Antigen Discovery for Complex Disease Progression

Matthias Von Herrath
Vice President & Senior Medical Officer, Global Chief Medical Officer
Novo Nordisk

Day Two

Thursday February 27, 2020

11:30 am | Treg-Enhancing Approaches to Drive Tolerance Induction in the Clinic

Ranjeny Thomas
Professor of Rheumatology
University of Queensland, Translational Research Institute

Day Two

Thursday February 27, 2020

2:00 pm | Delivery of Autoantigenic peptides/proteins to APCs Using Nanoparticle Vehicles; Challenges In the Pursuit of Immune Tolerance in Progressive Autoimmune Diseases

Bruna Barneda
Pre-Clinical & Clinical Development Director
Ahead Therapeutics

Day Two

Thursday February 27, 2020

12:00 pm | PS-LIPOSOMES, a Flexible Tech-Platform to Induce Antigen- Specific Immune Tolerance

Andreas Lutterotti
Head of Experimental Therapies Research
University Hospital Zurich

Day One

Wednesday February 26, 2020

10:30 am | Challenges in Defining & Measuring Immunological Tolerance in the Long Term

Stuart Mannering
ASI Visiting Speaker Program Coordinator, Head, Human T-cell Laboratory Immunology and Diabetes Unit
St. Vincent’s Institute of Medical Research

Vincent Dioszeghy
Researcher
DBV Technologies

Day Two

Thursday February 27, 2020

10:10 am | Combination therapy with Tregitope and Cashew Improves & Accelerates Therapeutic Effects of Epicutaneous Immunotherapy in a Robust Mouse Model of Cashew Allergy